News coverage about Puma Biotechnology (NASDAQ:PBYI) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Puma Biotechnology earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.4787412064584 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $19.35 Million (americanbankingnews.com)
- Why is Puma (PBYI) Stock Up More than 150% in a Year's Time? (finance.yahoo.com)
- Puma Biotechnology (PBYI) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Zacks: Analysts Expect Puma Biotechnology Inc (PBYI) to Announce -$2.02 Earnings Per Share (americanbankingnews.com)
- Puma Biotech (PBYI) to Modify Neratinib MAA Based on Feedback … – StreetInsider.com (streetinsider.com)
Several research firms recently weighed in on PBYI. JPMorgan Chase & Co. restated a “buy” rating and issued a $131.00 target price on shares of Puma Biotechnology in a report on Wednesday, October 4th. Credit Suisse Group set a $142.00 target price on Puma Biotechnology and gave the stock a “buy” rating in a report on Monday. Bank of America restated a “buy” rating and issued a $135.00 target price (up from $117.00) on shares of Puma Biotechnology in a report on Monday, October 9th. Barclays restated a “buy” rating and issued a $122.00 target price (up from $103.00) on shares of Puma Biotechnology in a report on Friday, November 10th. Finally, Royal Bank of Canada cut their price target on Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a report on Friday, November 10th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. Puma Biotechnology currently has a consensus rating of “Buy” and an average target price of $130.67.
Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The firm had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the prior year, the firm posted ($1.11) earnings per share. sell-side analysts forecast that Puma Biotechnology will post -8.17 EPS for the current year.
In other news, insider Charles R. Eyler sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 21.10% of the company’s stock.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.